Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEALTH Trial: Ivermectin Bioequivalence in Healthy Adults
NCT06918665Phase 1Suspended
- Sponsor
- Murdoch Children's Research Institute
- Start
- Jan 2027
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of CHILD-IVITAB in scabies (2 arms), sponsored by Murdoch Children's Research Institute. Primary endpoints: Area Under the Curve from 0 to 96 hours and Maximum Concentration at 31 days. Planned start Jan 2027; status: suspended.
02
Drugs
CHILD-IVITAB
03
Conditions
scabies
Beyond the preview
Go deeper on NCT06918665.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06918665.